Royalty Pharma Statistics
Total Valuation
Royalty Pharma has a market cap or net worth of $39.76 billion. The enterprise value is $47.80 billion.
| Market Cap | 39.76B |
| Enterprise Value | 47.80B |
Important Dates
The last earnings date was Wednesday, November 4, 2026, before market open.
| Earnings Date | Nov 4, 2026 |
| Ex-Dividend Date | Nov 13, 2026 |
Share Statistics
Royalty Pharma has 573.61 million shares outstanding. The number of shares has decreased by -16.87% in one year.
| Current Share Class | 445.27M |
| Shares Outstanding | 573.61M |
| Shares Change (YoY) | -16.87% |
| Shares Change (QoQ) | +0.02% |
| Owned by Insiders (%) | 6.20% |
| Owned by Institutions (%) | 85.24% |
| Float | 417.10M |
Valuation Ratios
The trailing PE ratio is 45.26 and the forward PE ratio is 10.68. Royalty Pharma's PEG ratio is 1.22.
| PE Ratio | 45.26 |
| Forward PE | 10.68 |
| PS Ratio | 15.18 |
| Forward PS | 10.59 |
| PB Ratio | 4.50 |
| P/TBV Ratio | 6.72 |
| P/FCF Ratio | 13.42 |
| P/OCF Ratio | 13.42 |
| PEG Ratio | 1.22 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 28.26, with an EV/FCF ratio of 16.14.
| EV / Earnings | 71.03 |
| EV / Sales | 18.25 |
| EV / EBITDA | 28.26 |
| EV / EBIT | 28.34 |
| EV / FCF | 16.14 |
Financial Position
The company has a current ratio of 1.29, with a Debt / Equity ratio of 0.88.
| Current Ratio | 1.29 |
| Quick Ratio | 1.29 |
| Debt / Equity | 0.88 |
| Debt / EBITDA | 5.08 |
| Debt / FCF | 2.90 |
| Interest Coverage | 4.53 |
Financial Efficiency
Return on equity (ROE) is 12.09% and return on invested capital (ROIC) is 5.70%.
| Return on Equity (ROE) | 12.09% |
| Return on Assets (ROA) | 5.43% |
| Return on Invested Capital (ROIC) | 5.70% |
| Return on Capital Employed (ROCE) | 9.22% |
| Weighted Average Cost of Capital (WACC) | 5.72% |
| Revenue Per Employee | $26.17M |
| Profits Per Employee | $6.72M |
| Employee Count | 100 |
| Asset Turnover | 0.13 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +75.07% in the last 52 weeks. The beta is 0.36, so Royalty Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.36 |
| 52-Week Price Change | +75.07% |
| 50-Day Moving Average | 61.51 |
| 200-Day Moving Average | 54.63 |
| Relative Strength Index (RSI) | 72.18 |
| Average Volume (20 Days) | 3,410,800 |
Short Selling Information
The latest short interest is 13.08 million, so 2.28% of the outstanding shares have been sold short.
| Short Interest | 13.08M |
| Short Previous Month | 12.84M |
| Short % of Shares Out | 2.28% |
| Short % of Float | 3.13% |
| Short Ratio (days to cover) | 4.05 |
Income Statement
In the last 12 months, Royalty Pharma had revenue of $2.62 billion and earned $672.45 million in profits. Earnings per share was $1.53.
| Revenue | 2.62B |
| Gross Profit | 2.61B |
| Operating Income | 1.69B |
| Pretax Income | 1.17B |
| Net Income | 672.45M |
| EBITDA | 1.69B |
| EBIT | 1.69B |
| Earnings Per Share (EPS) | $1.53 |
Balance Sheet
The company has $544.86 million in cash and $8.59 billion in debt, with a net cash position of -$8.04 billion or -$14.02 per share.
| Cash & Cash Equivalents | 544.86M |
| Total Debt | 8.59B |
| Net Cash | -8.04B |
| Net Cash Per Share | -$14.02 |
| Equity (Book Value) | 9.80B |
| Book Value Per Share | 15.34 |
| Working Capital | 346.56M |
Cash Flow
| Operating Cash Flow | 2.96B |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 4.88M |
| Net Borrowing | -380.00M |
| Free Cash Flow | 2.96B |
| FCF Per Share | $5.16 |
Margins
Gross margin is 99.79%, with operating and profit margins of 64.41% and 25.70%.
| Gross Margin | 99.79% |
| Operating Margin | 64.41% |
| Pretax Margin | 44.84% |
| Profit Margin | 25.70% |
| EBITDA Margin | 64.60% |
| EBIT Margin | 64.41% |
| FCF Margin | 113.11% |
Dividends & Yields
This stock pays an annual dividend of $0.94, which amounts to a dividend yield of 1.36%.
| Dividend Per Share | $0.94 |
| Dividend Yield | 1.36% |
| Dividend Growth (YoY) | 6.82% |
| Years of Dividend Growth | 5 |
| Payout Ratio | 61.38% |
| FCF Payout Ratio | 18.22% |
| Buyback Yield | 16.87% |
| Shareholder Yield | 18.23% |
| Earnings Yield | 2.21% |
| FCF Yield | 7.45% |
Analyst Forecast
The average price target for Royalty Pharma is $72.00, which is 3.88% higher than the current price. The consensus rating is "Buy".
| Price Target | $72.00 |
| Price Target Difference | 3.88% |
| Analyst Consensus | Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (3Y) | 20.52% |
| EPS Growth Forecast (3Y) | 10.92% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |
| Graham Formula Value | |
| Graham Formula Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Royalty Pharma has an Altman Z-Score of 1.93 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.93 |
| Piotroski F-Score | 6 |